PROK 주가 차트
PROK 재무
Prokidney Corp
$1.83
4.57%
$0.08
종가: Jun 18, 16:00:00 GMT-4
$1.81
-1.09%
$-0.02
애프터마켓: Jun 18, 20:00:00 GMT-4
뒤로
Prokidney Corp (PROK) 재무
주요 통계
이전 종가
$1.75
시가
$1.76
일일 범위
$1.75 - $1.83
52주 범위
$0.54 - $7.13
거래량
559.8K
평균 거래량
850.0K
배당수익률
--
EPS(TTM)
-0.53
시가총액
$546.7M
PROK란 무엇인가요?
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 231 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
